$68.51
0.93% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US4576693075
Symbol
INSM
Sector
Industry

Insmed Incorporated Stock price

$68.51
-1.00 1.44% 1M
-4.16 5.72% 6M
-0.53 0.77% YTD
+42.97 168.25% 1Y
+48.26 238.32% 3Y
+42.46 162.99% 5Y
+45.37 196.07% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.63 0.93%
ISIN
US4576693075
Symbol
INSM
Sector
Industry

Key metrics

Market capitalization $12.48b
Enterprise Value $12.59b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 33.04
P/S ratio (TTM) P/S ratio 32.75
P/B ratio (TTM) P/B ratio 125.68
Revenue growth (TTM) Revenue growth 20.77%
Revenue (TTM) Revenue $381.03m
EBIT (operating result TTM) EBIT $-859.01m
Free Cash Flow (TTM) Free Cash Flow $-789.25m
Cash position $1.20b
EPS (TTM) EPS $-5.95
P/E forward negative
P/S forward 26.75
EV/Sales forward 26.98
Short interest 9.78%
Show more

Is Insmed Incorporated a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Insmed Incorporated Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Insmed Incorporated forecast:

19x Buy
100%

Analyst Opinions

19 Analysts have issued a Insmed Incorporated forecast:

Buy
100%

Financial data from Insmed Incorporated

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
381 381
21% 21%
100%
- Direct Costs 95 95
27% 27%
25%
286 286
19% 19%
75%
- Selling and Administrative Expenses 504 504
47% 47%
132%
- Research and Development Expense 630 630
12% 12%
165%
-848 -848
27% 27%
-222%
- Depreciation and Amortization 11 11
27% 27%
3%
EBIT (Operating Income) EBIT -859 -859
26% 26%
-225%
Net Profit -1,013 -1,013
36% 36%
-266%

In millions USD.

Don't miss a Thing! We will send you all news about Insmed Incorporated directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Insmed Incorporated Stock News

Neutral
Seeking Alpha
12 days ago
Insmed Incorporated (NASDAQ:INSM ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Bryan Dunn - Investor Relations Will Lewis - Chair and Chief Executive Officer Sara Bonstein - Chief Financial Officer Martina Flammer - Chief Medical Officer Conference Call Participants Andrea Newkirk - Goldman Sachs Jason Zemansky - Bank of America Nick Lenard - JPMorgan Joe Schwar...
Neutral
PRNewsWire
13 days ago
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $92.8 Million for the First Quarter of 2025, Reflecting 23% Growth Over the First Quarter of 2024— —NDA for Brensocatib in Patients with Bronchiectasis Remains on Track, with a PDUFA Target Action Date of August 12, 2025— —Phase 2b Study of TPIP in Patients with PAH Completed; Topline Data Expected in June 2025— —Enrollment C...
Positive
Seeking Alpha
22 days ago
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained a...
More Insmed Incorporated News

Company Profile

Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Head office United States
CEO Will Lewis
Employees 1,271
Founded 1988
Website www.insmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today